NightHawk Biosciences Overview
NightHawk Biosciences (NHWK) has a ROE of 3662.31%, above the Healthcare sector average of 22.76%.
Get informed when a big investor buys or sells
+ Follow3662.31%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for NHWK is 3662.31%. That is above the Healthcare sector average of 22.76%. Investors often review this figure alongside NightHawk Biosciences's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, NHWK currently prints 3662.31% for ROE, while the sector average sits near 22.76%. That is roughly 15988.2% above the sector mean. Large gaps often invite a closer look at NightHawk Biosciences's growth, margins, and balance sheet.
Return on Equity shows how effectively NightHawk Biosciences converts resources into returns. At 3662.31%, NHWK may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting NHWK's ROE (3662.31%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack NightHawk Biosciences's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
